Sunday, 24 March 2019

Biocon API facility in Telangana completes USFDA inspection

17 December 2018 | News

The inspection concluded without any observations and no Form 483 was issued.

Biocon Ltd, Asia’s premier biopharmaceuticals company, has recently announced that the USFDA conducted a Good Manufacturing Practice (GMP) inspection of the APIs manufacturing facility at Telangana from Dec 12- Dec 14, 2018. The inspection concluded without any observations and no Form 483 was issued.

According to the company, the successful inspection of this site reflects their strong commitment to quality and Current Good Manufacturing Practice (cGMP) compliance.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Can collaboration between startups and big life sciences companies offer a disruptive breakthrough?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls